Vaxxinit products

The Vaxxine Platform: Programming the immune system to fight disease; Vaxxinity’s innovative tech platform utilizes synthetic peptide immunogens linked to precision-engineered target antigens to activate the immune system against disease.  A modular platform, it can activate B- and T-cell arms of the immune system selectively, and even combine multiple antigens into a single formulation, or a “multitope vaccine.”

Targets toxic forms of aggregated Aβ in the brain to fight Alzheimer’s. Phase 1, Phase 2a and Phase 2a LTE trials have shown UB-311 to be well tolerated in early AD subjects over three years of repeat dosing, with a safety profile comparable to placebo, with no cases of amyloid-related imaging abnormalities-edema (“ARIA-E”) in the main study. Highly immunogenic with a high responder rate and antibodies that bind to the desired target. The FDA has granted UB-311 Fast Track Designation.

Targets toxic forms of aggregated α-synuclein in the brain to fight Parkinson’s and other synucleinopathies, such as dementia with Lewy Body (“DLB”) and multiple system atrophy (“MSA”). The first part of a Phase 1 trial in healthy volunteers has shown UB-312 to be well tolerated, with no significant safety findings, and immunogenic, with a high responder rate and antibodies that cross the blood-brain barrier (“BBB”).

We are developing an anti-tau product candidate that has the potential to address multiple neurodegenerative conditions, including AD, by targeting abnormal tau proteins alone and in potential combination with other pathological proteins such as Aβ to combat multiple pathological processes at once.

Targets CGRP to fight migraines. We have initiated IND-enabling studies.

Targets PCSK9 to lower LDL cholesterol and reduce the risk of cardiac events.

Employs a “multitope” approach to neutralizing the SARS-CoV-2 virus, eliciting a well-balanced B and T-cell response against multiple viral epitopes. Phase 1 and Phase 2 trials of UB-612 have shown UB-612 to be well tolerated, with no significant safety findings to date, and inducing neutralizing titers against Omicron and other variants of concern. UB-612 is now in a Phase 3 heterologous boost trial.

Our Vaxxine Platform is designed to harness the immune system to convert the body into its own natural “drug factory” stimulating the production of antibodies. Our technology uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance”, or the body’s tendency to avoid attacking molecules within your own body even if they’re harmful. Traditional vaccine technologies have to date fallen short in attempts to achieve this due to insufficient responses and side effects.